business plan executive summary - biohope.eu · the market size | immunobiogram® market global ivd...
TRANSCRIPT
Business Plan Executive Summary
Biohope is a start-up biomedical company focused in the research and development of novel clinical management tools.
MAJOR MILESTONES BUSINESS MODEL STRATEGYMANAGEMENTBUSINESS PLANCONCLUSIONS
Contents:PROBLEMSOLUTIONMARKET SIZEPRODUCTCOMPETITION
Problem | CHRONIC INFLAMMATORY CONDITIONS
RENAL TRANSPLANT RHEUMATOID ARTHRITIS
With deficient clinical evolution in transplants show a clear resistance to the drugs they take.
Have bad clinical evolution, ending with di�erent types of disabilities.
Are LOST in 10 years due to rejection.
60%of
patients
50%of
transplantedorgans
years
Of life expectancy can be lost.
4-10
30%of
patients
Problem | AN UNMET MEDICAL NEED IN PATIENTS WITH CHRONIC INFLAMMATORY DISEASES
NO personalization,NO precision
Treatment with immunosuppressive and/or immunomodulatory therapies.
Generalguidelines and recommendations.
Loss of time and accuracyIncreased health costsIncreased side e�ects due to suboptimal medicationWorsening of the prognosis
The Solution | IMMUNOBIOGRAM®
Better clinicaloutcomes
Reduction ofside e�ects
Improve patientquality of life
Reduction ofhealth costs
A disruptive blood-based in vitro diagnosis device for the design of a PERSONALIZED immunosuppressant therapy to treat patients with chronic inflammatory diseases.
THE MARKET SIZE |
IMMUNOBIOGRAM® MARKET
GLOBAL IVD MARKET
Our core target is a market of 22M patients worldwide, patients with Renal Transplant and Rheumatoid Arthritis.
2 MillRenal
Transplants
20 MillRheumatoid
Arthritis
Annual profits
1% of world population,30% bad clinical evolution.
74 B$ in 2017 104 B$ in 2022**** Forecast
6,7% annual growth
OUR PRODUCT IMMUNOBIOGRAM® |
PROGNOSIS AND MONITORING KIT
Blood sample
Laboratory STANDARD- Fluorimeter
Biohope software web hosted (Algorithm & Database)
Biologicalprocess3-7 days
User Report: Self-explanatory, resistance/sensibility to di�erent drugs and recommendations. Generated by hospital´s immunology Lab and signed by authorized sta�.
COMPETITION |
only provides information about
global excess or scarcity of inmunosuppression.
IMMUNOBIOGRAM® is a IVD test based in a unique technology that will allow the selection of the optimal immunosuppressive therapy (combination of drugs / dosage) for each patient.
Immunobiogram® has not competitor providing similar information.
Which drugs? Which doses? For Renal Transplants
Rheumatoid Arthritis
MAJOR MILESTONES |
2016-2107 2019
2018 2020Prototypealready tested with beta user interface.
International Study in RAProduction Validation RT
InternationalStudy in RA
ProductionValidation RT
Publication + protection
European patent: 4 applications submitted.
Successfully finisheda National Study in RT with La Paz and Puerta de Hierro hospitals.
International Multicenter (4EU + 1 USA) Clinical Study
has been alreadylaunched for RT.National Study
in RA will be finished.
PCT Submission.
Sales RTCE Mark RT Sales RA2021
2022
BUSINESS MODEL STRATEGY |
Biohope business model is based on R&D for the Immunobiogram®, production will be externalized and commercialization will be thorough license agreements. Biohope will sell an IVD kit in 2020
Core BusinessR+DIP Strategy Medical A�airs RegulatoryBusiness Development
Production IVDkit externalized
Sales Immunobiogram®
kits
Clients / Partners agreements
Customers/Payers Users/DoctorsManufacturer
Biohope
Biohope
MANAGEMENT AND STAFF |
Dr. Isabel Portero, the founder of the company and currently the CEO, is a PhD in Medicine with a sound background in the biomedical field, who before founding Biohope acquired an extensive experience as Medical and R&D Director for di�erent hospitals, foundations, universities and biomedical/pharma companies, some of them in the Big Pharma industry like MSD or Roche.
Flexible organizational structure.Cover all required areas to achieve milestones.Management has seniors profiles with proven results in their area of expertise.
Francisco TejeraFINANCIAL DIRECTOR
Ricardo BrageBUSINESS DEVELOPMENT
DIRECTOR
José RichterTECHNICAL AND
DEVELOPMENT DIRECTOR
Gerardo EntrenaLEGAL AFFAIRS
DIRECTOR OF BIOHOPE
STAFF
10 YEARS BUSINESS PLAN FOR 2027 |
600
500
400
300
200
100
02018 2019 2020 2021 2022 2023 2024 2025 2026 2027
13 3161
109
158
211
263
329
399
INCOME Gross Margin Cash at Banks Earned Value
€497 M
€307 M
€170 M
* Consolidated for 2 indications: Renal Transplant and Rheumatoid Arthritis
Gross Margin
Earned Value
INCOME
5 REASONS TO INVEST IN BIOHOPE |
1
Large, growing, profitable and unsatisfied market with no relevant direct competitors.
2
Breakthrough precision medine product adding value to physicians, patients and payers.
3
Solid business model with strong focus on core activities to achieve business and financial milestones.
4
High level of scientific partners and Public Institutions.
5
Strong professional and highly comitted Team.
PRECISION MEDICINE GIVING HOPE